Search Results

Displaying Results 1-1 of 1 "'PLRX'"
Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.
Atisama Therapeutics Advances RB042 into Multiple Ascending Dose cohorts of Phase 1 Trial and Appoints Bernard Coulie as Chair of the Board

May 15, 2026, 10:25 ET Atisama Therapeutics Advances RB042 into Multiple Ascending Dose cohorts of Phase 1 Trial and Appoints Bernard Coulie as Chair of the Board

development and the Company prepares for its next phase of growth.Dr. Coulie currently serves as President and CEO of Pliant Therapeutics (NASDAQ: PLRX), a clinical-stage biopharmaceutical company focused on the development of integrin-based therapies, and holds board positions at several global biotech

More news about: Atisama Therapeutics

Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.